Continuous Glucose Monitoring (CGM) Devices are generally safe and well-tolerated by patients. However, they do have some limitations. CGM devices are not as accurate as laboratory blood glucose measurements, and there is a time lag between changes in blood glucose levels and changes in interstitial fluid glucose levels. Patients should be aware of these limitations when interpreting their glucose level data. In addition, Continuous Glucose Monitoring (CGM) Devices can be expensive, and not all insurance plans cover the cost of CGM devices. However, many patients find that the benefits of using a Continuous Glucose Monitoring (CGM) Devices outweigh the costs.
The graphical display and customizable alarms on Continuous Glucose Monitoring (CGM) Devices show a complete picture of glucose trends and notify users to any changes in glucose status. According to Coherent Market Insights, the Continuous Glucose Monitoring (CGM) Devices Market is anticipated to reach US$ 8,865.65 million in 2022 and grow at a CAGR of 24.8% during the following five years (2022-2030).
